近日，复宏汉霖（2696.HK）应邀出席2025中国医药决策者峰会（2025CHDC）暨中国创新药十年成就巡礼活动。会上公布了“中国创新药十年荣耀”系列榜单，复宏汉霖凭借卓越的创新实力与全球布局，荣膺“行业引领Biotech企业”奖项；其自主研发的抗PD-1单抗H药 汉斯状®（斯鲁利单抗）亦获评“行业引领创新药品”。复宏汉霖执行董事、首席执行官朱俊博士受邀出席峰会圆桌论坛，围绕“中国FIC创新药：...
Source Link近日，复宏汉霖（2696.HK）应邀出席2025中国医药决策者峰会（2025CHDC）暨中国创新药十年成就巡礼活动。会上公布了“中国创新药十年荣耀”系列榜单，复宏汉霖凭借卓越的创新实力与全球布局，荣膺“行业引领Biotech企业”奖项；其自主研发的抗PD-1单抗H药 汉斯状®（斯鲁利单抗）亦获评“行业引领创新药品”。复宏汉霖执行董事、首席执行官朱俊博士受邀出席峰会圆桌论坛，围绕“中国FIC创新药：...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.